ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours
The European Neuroendocrine Tumor Society consensus on lung carcinoids covers diagnosis, grading into typical and atypical, surgery with node dissection, and the limited evidence for somatostatin analogues, everolimus and radioligand therapy in advanced disease.
Overview
Expert consensus from the European Neuroendocrine Tumor Society on the classification, staging, imaging, surgical and systemic management of typical and atypical lung carcinoids, including recommendations on adjuvant therapy (not indicated), somatostatin analogues, everolimus, temozolomide-based chemotherapy and peptide receptor radionuclide therapy.
Surgical resection as the only curative treatment and the sequence of systemic options on the lung neuroendocrine tumour page follow this consensus.
- Randomised evidence in lung carcinoids remains scarce; RADIANT-4 and CABINET are the main trials since.